HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by d‘Amato, T. A. Articles by Luketich, J. D. Search for Related Content PubMed PubMed Citation Articles by d‘Amato, T. A. Articles by Luketich, J. D. Related Collections Lung - cancer Molecular biology Related Article

J Thorac Cardiovasc Surg 2007;133:352-363
© 2007 The American Association for Thoracic Surgery

General Thoracic Surgery

Chemotherapy resistance and oncogene expression in non–small cell lung cancer

^a Jefferson Medical College, Division of Cardiothoracic Surgery, Philadelphia, Pa
^b University of Pittsburgh Medical Center Presbyterian-Shadyside, Heart, Lung and Esophageal Surgery Institute, Pittsburgh, Pa
^c Oncotech, Inc, Tustin, Calif.

Read at the Thirty-second Annual Meeting of the Western Thoracic Surgical Association, Sun Valley, Idaho, June 21-24, 2006.

Received for publication June 19, 2006; revisions received September 25, 2006; accepted for publication October 9, 2006.

^_* Address for reprints: Thomas A. d’Amato, MD, PhD, Division of Cardiothoracic Surgery, Jefferson Medical College of Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA 19107. (Email: thomas.damato{at}jefferson.edu).

OBJECTIVES: Empiric chemotherapy for patients with non–small cell lung cancer who have undergone resection is recommended without knowledge of the tumor’s specific biologic characteristics, and many patients may not benefit. In vitro chemotherapy resistance is associated with clinical unresponsiveness in some tumors, and in lung cancer, chemotherapy resistance is prevalent. Multiple-agent chemotherapy resistance and association of chemotherapy resistance with molecular markers are described.

METHODS: Chemotherapy resistance to doublets—carboplatin and paclitaxel, cisplatin and navelbline, cisplatin and docetaxel, and cisplatin and gemcitabine—was analyzed in 4571 non–small cell lung cancer tumors with the extreme drug resistance assay. Chemotherapy resistance is defined as follows: extreme drug resistance, 1 SD above the median chemotherapy resistance; intermediate drug resistance, between the median and extreme drug resistances; and low drug resistance, 1 SD below the median. Chemotherapy resistance was compared with DNA ploidy measured by flow cytometry, and markers p53 and epithelial growth factor receptor were assayed by immunohistochemistry.

RESULTS: Tumors with extreme or intermediate drug resistance were noted in 30% to carboplatin-paclitaxel, in 24% to cisplatin-navelbline, in 42% to cisplatin-gemcitabine, and in 27% to cisplatin-docetaxel. Extreme or intermediate drug resistance to at least one drug occurred in 74% to carboplatin-paclitaxel, in 68% to cisplatin-navelbline, in 88% to cisplatin-gemcitabine, and in 68% to cisplatin-docetaxel. More intermediate plus extreme chemotherapy resistances occurred in aneuploid tumors to etoposide (53% vs 36%, P = .0002) and topotecan (48% vs 36%, P = .0094), with less intermediate or extreme chemotherapy resistance to gemcitabine (88% vs 81%, P = .0345). p53-Positive tumors had more intermediate or extreme resistance to etoposide (57% vs 44%, P = .0009) and doxorubicin (73% vs. 58%, P = .0324) and less intermediate or extreme resistance to cisplatin (44% vs 54%, P = .0125), to carboplatin (47% vs 57%, P = .0129), to taxol (47% vs 57%, P = .0056), and to gemcitabine (78% vs 87%, P = .0108). Fewer epithelial growth factor receptor–positive tumors were extremely drug resistant to cisplatin (13% vs 26%, P = .0074) and carboplatin (13% v. 30%, P = .0008).

CONCLUSIONS: Multi-drug chemotherapy resistance in non–small cell lung cancer tumor cultures is common, and associations between molecular markers and in vitro chemotherapy resistance are noted. Clinical validation through integration of such testing into clinical trials seems warranted.

Related Article

Discussion
J. Thorac. Cardiovasc. Surg. 2007 133: 361-363. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				A. A. Mujoomdar, T. R. Tilleman, W. G. Richards, R. Bueno, and D. J. Sugarbaker Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens. J. Thorac. Cardiovasc. Surg., August 1, 2010; 140(2): 352 - 355. [Abstract] [Full Text] [PDF]

				S. S. More, S. Li, S. W. Yee, L. Chen, Z. Xu, D. M. Jablons, and K. M. Giacomini Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue Mol. Cancer Ther., April 1, 2010; 9(4): 1058 - 1069. [Abstract] [Full Text] [PDF]

				J. M. Serra, A. Gutierrez, R. Alemany, M. Navarro, T. Ros, C. Saus, J. Gines, A. Sampol, J. C. Amat, L. Serra-Moises, et al. Inhibition of c-Myc Down-Regulation by Sustained Extracellular Signal-Regulated Kinase Activation Prevents the Antimetabolite Methotrexate- and Gemcitabine-Induced Differentiation in Non-Small-Cell Lung Cancer Cells Mol. Pharmacol., June 1, 2008; 73(6): 1679 - 1687. [Abstract] [Full Text] [PDF]

				D. Kandioler, G. Stamatis, W. Eberhardt, S. Kappel, S. Zochbauer-Muller, I. Kuhrer, M. Mittlbock, R. Zwrtek, C. Aigner, C. Bichler, et al. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., May 1, 2008; 135(5): 1036 - 1041. [Abstract] [Full Text] [PDF]